DAWN
Day One Biopharmaceuticals, Inc.Company with tickers: DAWN
CIK
1845337
CUSIP
23954D109
Shares Outstanding
103,334,169
13F Activity (30d)
143 filings
138 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $158,182,000 | USD | 2025-12-31 | 10-K | 2026-02-24 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $285,932,000 | USD | 2025-12-31 | 10-K | 2026-02-24 |
| Research & Development | $148,135,000 | USD | 2025-12-31 | 10-K | 2026-02-24 |
| Operating Income | $-127,750,000 | USD | 2025-12-31 | 10-K | 2026-02-24 |
| Net Income | $-107,322,000,000 | USD | 2025-12-31 | 10-K/A | 2026-04-17 |
| EPS (Basic) | $-1.04 | USD/shares | 2025-12-31 | 10-K | 2026-02-24 |
| EPS (Diluted) | $-1.04 | USD/shares | 2025-12-31 | 10-K | 2026-02-24 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Product & Service (USD)
| Component | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Product | $0 | $57,217,000 | $155,421,000 |
| License | $0 | $73,944,000 | $2,761,000 |